|
MX359371B
(es)
|
2001-11-13 |
2018-09-25 |
Univ Pennsylvania |
Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
MX374963B
(es)
|
2011-04-29 |
2025-03-06 |
Selecta Biosciences Inc |
Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
|
|
HK1202434A1
(en)
|
2011-11-22 |
2015-10-02 |
The Children's Hospital Of Philadelphia |
Virus vectors for highly efficient transgene delivery
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
US9539307B2
(en)
|
2012-09-17 |
2017-01-10 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
HK1220488A1
(zh)
|
2013-03-15 |
2017-05-05 |
The Children's Hospital Of Philadelphia |
含有填充者/填充物多核苷酸序列的载体及其使用方法
|
|
BR122020023215B1
(pt)
|
2013-05-03 |
2022-11-22 |
Selecta Biosciences, Inc |
Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
|
|
IL297919A
(en)
*
|
2013-07-22 |
2023-01-01 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
US9725719B2
(en)
|
2013-11-05 |
2017-08-08 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
PL3628334T3
(pl)
*
|
2014-03-21 |
2023-12-18 |
Genzyme Corporation |
Terapia genowa w retinopatii barwnikowej
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CN105396143B
(zh)
*
|
2014-09-01 |
2020-06-26 |
江苏命码生物科技有限公司 |
埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法
|
|
JP7242180B2
(ja)
*
|
2014-09-07 |
2023-03-20 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
ES2799515T3
(es)
|
2015-05-22 |
2020-12-18 |
Dmitry Dmitrievich Genkin |
ADN extracelular como una diana terapéutica en la neurodegeneración
|
|
MX390848B
(es)
|
2015-06-23 |
2025-03-21 |
Childrens Hospital Philadelphia |
Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
|
|
CN107921067A
(zh)
*
|
2015-07-10 |
2018-04-17 |
杜克大学 |
用于治疗疼痛的方法
|
|
IL258005B2
(en)
|
2015-09-17 |
2025-01-01 |
Res Inst Nationwide Childrens Hospital |
Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2
|
|
TW202446416A
(zh)
|
2015-09-24 |
2024-12-01 |
美商拜奧馬林製藥公司 |
腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
|
|
ES2879400T3
(es)
*
|
2015-10-21 |
2021-11-22 |
Us Health |
ADNc de ATP7A de tamaño reducido con codones optimizados y usos para el tratamiento de trastornos del transporte de cobre
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EA202190827A1
(ru)
|
2015-11-13 |
2021-11-30 |
Баксалта Инкорпорейтед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
|
|
CA3005565A1
(en)
|
2015-11-13 |
2017-05-18 |
Baxalta Incorporated |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
KR102877920B1
(ko)
|
2015-11-16 |
2025-10-30 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
|
|
EP3384015A4
(en)
*
|
2015-12-01 |
2019-05-29 |
Spark Therapeutics, Inc. |
SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION
|
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
|
|
AU2016366560A1
(en)
*
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017173043A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
LT3442600T
(lt)
*
|
2016-04-15 |
2024-05-27 |
Research Institute At Nationwide Children's Hospital |
Su adeno virusu susijusio viruso vektoriaus iš β-sarkoglikano ir mikro- rnr-29 pristatymas ir raumenų distrofijos gydymas
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
IL305149A
(en)
|
2016-07-26 |
2023-10-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
|
|
CN106344932B
(zh)
*
|
2016-08-26 |
2019-12-27 |
首都医科大学附属北京同仁医院 |
一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
WO2018082093A1
(en)
*
|
2016-11-07 |
2018-05-11 |
Wuhan Institute Of Virology, Chinese Academy Of Sciences |
Anterograde monosynaptic transneuronal tracer system
|
|
BR112019013245A2
(pt)
|
2016-12-30 |
2020-02-11 |
The Trustees Of The University Of Pennsylvania |
Terapia gênica para tratamento da doença de wilson
|
|
JP7215716B2
(ja)
|
2017-01-13 |
2023-01-31 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
JOP20190200A1
(ar)
*
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
EP3589307B1
(en)
*
|
2017-02-28 |
2022-02-16 |
The Penn State Research Foundation |
Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
|
|
RU2019130004A
(ru)
*
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия при глазных заболеваниях
|
|
ES3036482T3
(en)
|
2017-03-11 |
2025-09-19 |
Cartesian Therapeutics Inc |
Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
|
|
EP3596112A2
(en)
|
2017-03-17 |
2020-01-22 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
JP7676111B2
(ja)
*
|
2017-03-17 |
2025-05-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
|
|
MX2019011772A
(es)
|
2017-04-03 |
2020-01-09 |
Encoded Therapeutics Inc |
Expresion transgenica selectiva de tejidos.
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
AU2018269050A1
(en)
*
|
2017-05-19 |
2020-01-16 |
Encoded Therapeutics, Inc. |
High activity regulatory elements
|
|
CN110945127B
(zh)
|
2017-05-22 |
2024-07-12 |
武田药品工业株式会社 |
用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US20200164008A1
(en)
*
|
2017-07-17 |
2020-05-28 |
Spark Therapeutics, Inc. |
Apheresis methods and uses
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
NZ762100A
(en)
|
2017-08-09 |
2025-12-19 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
|
AU2018329741B2
(en)
|
2017-09-08 |
2025-02-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
CN107760719B
(zh)
*
|
2017-10-24 |
2020-09-22 |
北京领柯生物科技有限公司 |
柯萨奇病毒在过继免疫基因递送系统中的应用
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
EP3717505A4
(en)
|
2017-12-01 |
2021-12-01 |
Encoded Therapeutics, Inc. |
GENENICALLY MODIFIED DNA-BINDING PROTEINS
|
|
EP3728568A4
(en)
|
2017-12-19 |
2021-10-06 |
The University of North Carolina at Chapel Hill |
METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER
|
|
CA3086046C
(en)
|
2017-12-29 |
2023-02-21 |
Helixmith Co., Ltd. |
Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
|
|
AU2019209770B2
(en)
|
2018-01-16 |
2025-07-31 |
Cls Therapeutics Limited |
Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
|
|
AR114350A1
(es)
|
2018-01-31 |
2020-08-26 |
Res Institute At Nationwide ChildrenS Hospital |
Terapia genética para la distrofia muscular de cinturas del tipo 2c
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
MA51353B1
(fr)
|
2018-04-05 |
2022-09-30 |
Univ Sorbonne |
Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
TW202016314A
(zh)
|
2018-05-09 |
2020-05-01 |
美商拜奧馬林製藥公司 |
治療苯丙酮尿症之方法
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
KR20210028162A
(ko)
|
2018-06-29 |
2021-03-11 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
|
|
US12091675B2
(en)
|
2018-07-16 |
2024-09-17 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
|
|
EP3833766A1
(en)
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
US20220010333A1
(en)
*
|
2018-09-06 |
2022-01-13 |
The Regents Of The University Of California |
Rna and dna base editing via engineered adar recruitment
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
DK3906066T5
(da)
*
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
BR112021015751A2
(pt)
*
|
2019-02-12 |
2022-02-08 |
Spacecraft Seven Llc |
Vetores de terapia genética para tratamento da doença de danon
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
AU2020229340A1
(en)
|
2019-02-26 |
2021-09-16 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
|
|
SG11202109362XA
(en)
|
2019-02-28 |
2021-09-29 |
Encoded Therapeutics Inc |
Compositions and methods for treating laminopathies
|
|
CN109999182B
(zh)
*
|
2019-03-29 |
2023-03-07 |
四川大学华西医院 |
凝血因子在制备抗肿瘤药物中的应用
|
|
MX2021014226A
(es)
*
|
2019-05-20 |
2022-01-06 |
BioNTech SE |
Arn terapeutico para cancer de ovario.
|
|
PL3976798T3
(pl)
|
2019-05-29 |
2026-04-07 |
Encoded Therapeutics, Inc. |
Kompozycje i sposoby selektywnej regulacji genów
|
|
AU2020287627A1
(en)
|
2019-06-04 |
2021-11-18 |
Selecta Biosciences, Inc. |
Formulations and doses of PEGylated uricase
|
|
CA3140685A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Vijay G. Sankaran |
Compositions and methods for the treatment of dba using gata1 gene therapy
|
|
RS65421B1
(sr)
|
2019-08-21 |
2024-05-31 |
Res Inst Nationwide Childrens Hospital |
Isporuka adeno-asociranog virusnog vektora alfa-sarkoglikana i lečenje mišićne distrofije
|
|
EP4022057A1
(en)
|
2019-08-27 |
2022-07-06 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
|
US20220347318A1
(en)
*
|
2019-09-25 |
2022-11-03 |
University Of Utah Research Foundation |
Methods and compositions for the expression of constitutively active rap1a from a vmd2 promoter
|
|
AU2020356962A1
(en)
*
|
2019-10-02 |
2022-04-14 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
KR20220130093A
(ko)
*
|
2019-10-30 |
2022-09-26 |
데시벨 테라퓨틱스, 인크. |
오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
|
|
TWI902721B
(zh)
*
|
2019-11-04 |
2025-11-01 |
美商迪賽博治療公司 |
前庭支持細胞啟動子及其用途
|
|
WO2021096927A1
(en)
*
|
2019-11-13 |
2021-05-20 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Compositions and uses thereof for treating, prognosing and diagnosing pulmonary hypertension
|
|
JP2023503850A
(ja)
|
2019-11-14 |
2023-02-01 |
バイオマリン ファーマシューティカル インコーポレイテッド |
肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療
|
|
US20220409745A1
(en)
*
|
2019-11-19 |
2022-12-29 |
The Regents Of The University Of California |
Compositions and methods of using engineered fusion proteins that bind g4c2 human repeats
|
|
IL293012A
(en)
*
|
2019-11-20 |
2022-07-01 |
Bavarian Nordic As |
Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
|
|
AU2020388637A1
(en)
*
|
2019-11-21 |
2022-07-07 |
Remedium Bio, Inc. |
Growth factor restoration
|
|
AU2020395327A1
(en)
*
|
2019-12-05 |
2022-07-21 |
Cornell University |
Stabilization of retromer for the treatment of Alzheimer's disease and other neurodegenerative disorders
|
|
WO2021119538A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods for manufacture and uses thereof
|
|
JP7846007B2
(ja)
*
|
2019-12-18 |
2026-04-14 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物及び方法
|
|
GB201918879D0
(en)
*
|
2019-12-19 |
2020-02-05 |
Ucl Business Ltd |
Treatment of chronic pain
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
JP7703543B2
(ja)
*
|
2020-01-17 |
2025-07-07 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療
|
|
KR20220157944A
(ko)
|
2020-02-21 |
2022-11-29 |
아카우오스, 인크. |
인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
|
|
EP4114952A4
(en)
*
|
2020-03-05 |
2024-05-08 |
Board of Regents of the University of Nebraska |
Crispr/cas9 system for multistrain hiv-1 treatment
|
|
WO2021183755A1
(en)
*
|
2020-03-11 |
2021-09-16 |
City Of Hope |
Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
|
|
TW202144575A
(zh)
|
2020-04-03 |
2021-12-01 |
美商拜奧馬林製藥公司 |
使用ａａｖ及治療調配物之苯酮尿症治療
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
US12391745B2
(en)
|
2020-06-15 |
2025-08-19 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus antibodies and fragments thereof
|
|
US20230256117A1
(en)
*
|
2020-06-19 |
2023-08-17 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
|
JP2023532923A
(ja)
*
|
2020-06-30 |
2023-08-01 |
チルドレンズ ナショナル メディカル センター |
骨格筋線維の修復を改善するためのリコンビナントヒト酸性スフィンゴミエリナーゼの使用
|
|
CN111500635B
(zh)
*
|
2020-07-02 |
2020-10-09 |
北京大学第三医院（北京大学第三临床医学院） |
一种包含携带核酸分子的载体的试剂盒
|
|
CN116333984A
(zh)
*
|
2020-07-14 |
2023-06-27 |
广州泛恩生物科技有限公司 |
基于galnt2阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
|
|
CN111876432B
(zh)
*
|
2020-07-29 |
2022-10-28 |
舒泰神（北京）生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
KR20230043869A
(ko)
|
2020-08-07 |
2023-03-31 |
스페이스크래프트 세븐, 엘엘씨 |
Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
|
|
US20220096606A1
(en)
|
2020-09-09 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
|
|
US12071633B2
(en)
|
2020-10-13 |
2024-08-27 |
Kriya Therapeutics, Inc. |
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
|
|
US20220110970A1
(en)
*
|
2020-10-14 |
2022-04-14 |
The Texas A&M University System |
Engineered Extracellular Vesicle Delivery Systems and Uses Thereof
|
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
|
KR102803305B1
(ko)
*
|
2020-11-25 |
2025-05-07 |
연세대학교 산학협력단 |
트랜스-스플라이싱 아데노-연관 바이러스 벡터를 포함하는 프라임에디팅용 조성물
|
|
US20220238230A1
(en)
*
|
2021-01-15 |
2022-07-28 |
Trustees Of Tufts College |
Methods for modulating the function of biological regulatory networks in health and disease by exploiting their memory properties
|
|
TW202302848A
(zh)
|
2021-02-26 |
2023-01-16 |
美商維泰克斯製藥公司 |
以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
|
|
EP4298221A1
(en)
|
2021-02-26 |
2024-01-03 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
|
US20240165271A1
(en)
|
2021-03-26 |
2024-05-23 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
US20240252679A1
(en)
|
2021-05-28 |
2024-08-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
|
WO2023280175A1
(en)
*
|
2021-07-06 |
2023-01-12 |
National Institute Of Biological Sciences, Beijing |
Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
US20240408240A1
(en)
|
2021-10-01 |
2024-12-12 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
|
|
EP4219726A1
(en)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
JP2024540987A
(ja)
|
2021-10-21 |
2024-11-06 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
低免疫細胞
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
GB202202628D0
(en)
*
|
2022-02-25 |
2022-04-13 |
Babraham Inst |
Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
|
|
WO2023172927A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
AU2023255614A1
(en)
|
2022-04-18 |
2024-10-24 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver.
|
|
CN118460618A
(zh)
*
|
2022-04-19 |
2024-08-09 |
康霖生物科技（杭州）有限公司 |
一种用于遗传性凝血因子缺乏病治疗的核酸构建体
|
|
EP4558634A1
(en)
|
2022-07-18 |
2025-05-28 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
CN120380156A
(zh)
|
2022-09-22 |
2025-07-25 |
迪纳柯公司 |
用aav基因治疗载体治疗心肌病
|
|
KR20260019521A
(ko)
|
2023-05-25 |
2026-02-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Aav 정제 방법
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025214477A1
(en)
|
2024-04-12 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Treatment of genetic cardiomyopathies with aav gene therapy vectors
|